| Nov 19 |
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
|
| Nov 13 |
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
|
| Nov 13 |
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
GeoVax GAAP EPS of -$0.91 beats by $0.57, revenue of $2.79M beats by $1.87M
|
| Nov 12 |
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
GeoVax Labs initiated with a Buy at Alliance Global Partners
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
GeoVax Q3 Earnings Preview
|
| Nov 5 |
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
|
| Oct 9 |
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
